Evidence map›Paper›PMID 42038313›Full record

ArticleFrontiers in pharmacology2026

Non-viral gene therapy for hemophilia A: long-term outcomes of minicircle FVIII delivery in a mouse model.

Yung-Tsung Kao, Chih-Ching Yen, Gary Ro-Lin Chang, Hsin-Tse Chiang, Jen-Kun Chen, Muhammad Sufian, I-Chien Chen, Shang-Hsun Yang, Chuan-Mu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yung-Tsung Kao *Department of Life Sciences, and Doctorial Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Chih-Ching Yen *Department of Life Sciences, and Doctorial Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Gary Ro-Lin ChangDepartment of Life Sciences, and Doctorial Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Hsin-Tse ChiangDepartment of Life Sciences, and Doctorial Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Jen-Kun ChenPh.D. Program in Tissue Engineering and Regenerative Medicine, National Health Research Institutes and National Chung Hsing University, Taichung, Taiwan.
Muhammad SufianInstitute of Molecular Biology and Biotechnology (IMBB), The University of Lahore, Lahore, Pakistan.
I-Chien ChenDepartment of Life Sciences, and Doctorial Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.
Shang-Hsun YangDepartment of Physiology, Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan.
Chuan-Mu ChenDepartment of Life Sciences, and Doctorial Program in Translational Medicine, National Chung Hsing University, Taichung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophilia A, an X-linked bleeding disorder caused by factor VIII (FVIII) deficiency, necessitates lifelong factor replacement therapy with high treatment burden. To explore a non-viral alternative, we evaluated minicircle DNA carrying the FVIII-E1984V mutation-engineered for improved stability and activity-as a gene therapy for sustained coagulation correction. Mini-circle DNA constructs (with the bacterial backbone excised) encoding either wild-type FVIII or E1984V-FVIII were delivered

Indexed as

coagulation factor VIII (FVIII)E1984V point mutationhemophilia Amini-vectornon-viral gene therapy

Identifiers

PMID42038313
PMCPMC13102653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.